<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROGUANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROGUANIL" rxcui="2382">
<ATC code="P01BB01" />
<ATC code="P01BB51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>437-PROGUANIL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="PROGUANIL" rxcui="2382">
<ATC code="P01BB01" />
<ATC code="P01BB51" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THYROID HORMONES" code="H03AA" /></DRUG2>
<DESCRIPTION>Risk of clinically low thyroid with patients having thyroid replacement therapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
